In approximately 10 to 15 percent of congenital hemophilia A patients circulating antibodies to factor VIII appear in the blood that poses a serious problem in their treatment. A number of methods and preparations are used in the clinical practice to overcome this problem. Authors report their favourable clinical experience with the administration of polyelectrolyte-fractionated porcine factor VIII. concentrate in a hemophiliac child for the first time in Hungary and a brief review of the clinical methods in use in the management of factor VIII. inhibitors.
|Translated title of the contribution||Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A|
|Number of pages||3|
|Publication status||Published - Dec 26 1993|
ASJC Scopus subject areas